Outputs (3)

The efficacy of certain anti-tuberculosis drugs is affected by binding to alpha-1-acid glycoprotein. (2006)
Journal Article
Johnson, D. A., & Smith, K. (2006). The efficacy of certain anti-tuberculosis drugs is affected by binding to alpha-1-acid glycoprotein. Biomedical Chromatography, 20, 551-560. https://doi.org/10.1002/bmc.641

One of the most ubiquitous plasma proteins, -1-acid glycoprotein (AGP), has a high affinity, low capacity binding for basic drugs positively charged at physiological pH. Moreover, as an acute phase protein its level is increased in various disease st... Read More about The efficacy of certain anti-tuberculosis drugs is affected by binding to alpha-1-acid glycoprotein..

A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. (2002)
Journal Article
Anderson, N. E., Pollacchi, A., Hayes, P., Therapondos, G., Newsome, P., Boyter, A., & Smith, K. (2002). A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. Biomedical Chromatography, 16, 365-372. https://doi.org/10.1002/bmc.167

During the acute phase response (APR) to tissue injury or infection, the liver is responsible for the level of mediators such as cytokines required at the site of inflammation and providing the essential components for wound healing and tissue repair... Read More about A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases..

Alpha-1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. (2002)
Journal Article
Jørgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., & Smith, K. (2002). Alpha-1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99, 713-715. https://doi.org/10.1182/blood.V99.2.713

Despite the efficacy of STI571 (Glivec, Novartis, Basle, Switzerland) in treating chronic myeloid leukemia (CML), drug resistance has already been noted both in vitro and in vivo. As plasma proteins, including alpha-1-acid glycoprotein (AGP), may red... Read More about Alpha-1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571..